Cantor Fitzgerald Forecasts HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Harmony Biosciences in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of $3.71 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $58.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million for the quarter, compared to the consensus estimate of $184.07 million. During the same quarter in the prior year, the company earned $0.63 EPS. Harmony Biosciences’s quarterly revenue was up 16.0% on a year-over-year basis.

HRMY has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and issued a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Raymond James reiterated an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Harmony Biosciences in a report on Thursday, January 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday, January 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences currently has an average rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $38.66 on Wednesday. Harmony Biosciences has a twelve month low of $28.14 and a twelve month high of $41.61. The company’s 50 day moving average is $34.57 and its 200 day moving average is $35.02. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.20 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 0.54 and a beta of 0.78.

Insider Buying and Selling

In related news, insider Jeffrey Dierks sold 10,507 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 33,126 shares of company stock valued at $1,303,727. 30.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Harmony Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after buying an additional 436 shares in the last quarter. Mendota Financial Group LLC grew its holdings in shares of Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares in the last quarter. CWM LLC grew its holdings in shares of Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after buying an additional 775 shares in the last quarter. Quarry LP purchased a new stake in shares of Harmony Biosciences during the second quarter worth $62,000. Finally, KBC Group NV grew its holdings in shares of Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.